NASDAQ:CDT CDT Equity Q1 2025 Earnings Results & Report $0.34 -0.03 (-8.49%) As of 03:04 PM Eastern This is a fair market value price provided by Massive. Learn more. CDT Equity reported Q1 2025 earnings on May 15, 2025. The company reported EPS of -$19,800,000.00. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 15, 2025TimeBefore Market Opens CDT Equity EPS ResultsActual EPS-$19,800,000.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACDT Equity Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile CDT Equity Q1 2025 Earnings FAQ Did CDT Equity beat earnings estimates for Q1 2025? CDT Equity (NASDAQ:CDT) reported earnings of -$19,800,000.00 per share for Q1 2025. The report was announced on Thursday, May 15, 2025. CDT Equity Earnings HeadlinesCDT Equity Stockholders Approve Financing and Reverse Split ProposalsNovember 16 at 5:11 PM | tipranks.comCDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in VitiligoNovember 11, 2026 | globenewswire.comThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion a year in interest on it didn't change. Central banks bought 863 tonnes of gold in 2025 and another 289 tonnes in the second quarter of this year. Gold broke $5,000 and had its best year since 1979 in 2025. Wall Street's biggest bank forecasts gold above $6,000 by early 2027.November 17 at 1:00 AM | Vault Metal (Ad)CDT Equity Announces 1-for-20 Reverse Stock SplitNovember 4, 2026 | tipranks.comCDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded PeptidesOctober 30, 2026 | globenewswire.comCDT Equity Inc. reports third quarter 2026 results and announces $100 million data center agreement for 2027October 29, 2026 | msn.comSee More CDT Equity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email. Email Address About CDT EquityCDT Equity (NASDAQ:CDT) (NASDAQ: CDT) is associated with the former Conduit Pharmaceuticals, a biotechnology company focused on developing drug candidates for diseases with unmet medical needs. Conduit’s historical pipeline included compounds licensed from AstraZeneca, with research directed toward areas including inflammation and autoimmune disease. The company’s approach was to advance existing drug candidates rather than discover medicines entirely from scratch. Conduit had operations and a corporate presence in the United Kingdom and the United States. Because the company’s name and business status have changed, its historical biotechnology activities may not fully describe CDT Equity’s current operations.View CDT Equity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.